Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
Open Access
- 20 April 2004
- journal article
- case report
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (11) , 2059-2061
- https://doi.org/10.1038/sj.bjc.6601819
Abstract
Currently, there are no data on the secondary resistance of gastrointestinal stromal tumours to imatinib. Here, we report a case of metastatic gastrointestinal stromal tumour that relapsed during imatinib therapy. Mutation analysis showed that the imatinib-resistant liver tumour contained two c-kit mutations.Keywords
This publication has 5 references indexed in Scilit:
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.1999
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998